FDA Brief

Warning letters Food

FDA warning letter to

Herbal Vitality, Inc.

High riskIssued Mar 7, 2023Posted Mar 21, 2023Division of Human and Animal Food Operations West IV

FDA says Herbal Vitality's herbal tinctures were unapproved drugs and misbranded supplements.

What happened

FDA inspected Herbal Vitality's manufacturing facility in Sedona, Arizona, from July 11 through July 15, 2022, and reviewed finished product labels and the product catalog. FDA found the labels and catalog claimed many products would cure, treat, or prevent diseases such as kidney stones, cold and flu, Lyme disease, COPD, and other conditions, making them unapproved new drugs. FDA also found dietary supplement current good manufacturing practice (CGMP) violations, including missing contamination limits, missing finished-product specifications, releases without quality control review, and misbranded supplement labeling.

What FDA found

  1. FDA says many products were unapproved new drugs because their names and catalog claims said they cure, treat, or prevent diseases such as kidney stones, cold/flu, Lyme, and COPD.

    FD&C Act §§ 201(g)(1)(B), 201(p), 301(d), 505(a) [21 U.S.C. §§ 321(g)(1)(B), 321(p), 331(d), 355(a)]
  2. FDA says several products were misbranded drugs because they were for diseases a layperson cannot safely self-diagnose or treat, so adequate directions could not be written.

    FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]; § 301(a) [21 U.S.C. § 331(a)]
  3. FDA says the company did not set limits for microbes, pesticides, and heavy metals in components used in products such as Immune Tonic and Children’s Tonsillitis/Otitis.

    21 CFR 111.70(b)(3)
  4. FDA says the company did not set finished-product specifications for identity, purity, strength, composition, or contamination for any multi-ingredient supplement.

    21 CFR 111.70(e)
  5. FDA says batches were released for distribution without quality control review and approval.

    21 CFR 111.123(a)(8)
  6. FDA says supplement labels were misbranded, with missing ingredient names, wrong serving sizes, or incomplete Supplement Facts.

    FD&C Act § 403(i)(2), 403(q)(1)(A), 403(q)(5)(F) [21 U.S.C. § 343]; 21 CFR 101.4(h), 101.36

What FDA wants

FDA tells the company to correct the violations, including stopping disease claims and fixing manufacturing quality and labeling problems. The provided letter does not state a response deadline.

Who should pay attention

  • brands that buy herbal tinctures from contract manufacturers
  • retailers and distributors selling herbal supplements with disease claims
  • consumers, especially parents and pregnant people using these products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk